Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSinclair Pharma Regulatory News (SPH)

  • There is currently no data for SPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - Sinclair Pharma PLC

18 Oct 2018 15:20

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BYA PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Full name of discloser: Manikay Partners, LLC
(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

N/A
(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Sinclair Pharma PLC
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A
(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

17 October 2018
(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state “N/A”

No

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security: 1p ordinary

Interests Short positions
Number % Number %
(1) Relevant securities owned and/or controlled:

22,250,000

4.42%

(2) Cash-settled derivatives:
(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

TOTAL:

22,250,000

4.42%

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant security Purchase/sale Number of securities Price per unit
1p ordinary Purchase 22,250,000 0.315 GBP

(b) Cash-settled derivative transactions

Class of relevant security Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities Price per unit

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type

e.g. American, European etc.

Expiry date Option money paid/ received per unit

(ii) Exercise

Class of relevant security Product description

e.g. call option

Exercising/ exercised against Number of securities Exercise price per unit

(d) Other dealings (including subscribing for new securities)

Class of relevant security Nature of dealing

e.g. subscription, conversion

Details Price per unit (if applicable)

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

None

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state “none”

None

(c) Attachments

Is a Supplemental Form 8 (Open Positions) attached? No
Date of disclosure: 18 October 2018
Contact name: Lorelei Martin
Telephone number: (212) 588-6260

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

View source version on businesswire.com: https://www.businesswire.com/news/home/20181018005156/en/

Copyright Business Wire 2018

Date   Source Headline
5th Nov 20181:43 pmRNSForm 8.3 - Sinclair Pharma PLC
5th Nov 20187:30 amRNSSuspension - Sinclair Pharma Plc
5th Nov 20187:00 amRNSScheme of Arrangement becomes Effective
2nd Nov 201812:55 pmRNSPUBLIC DEALING DISCLOSURE
2nd Nov 201812:40 pmRNSPUBLIC DEALING DISCLOSURE
2nd Nov 201812:36 pmRNSRule 2.9 Announcement
2nd Nov 201812:00 pmRNSForm 8.5 (EPT/RI) - Sinclair Pharma Plc
2nd Nov 20187:44 amRNSForm 8.3 - Sinclair Pharma PLC
1st Nov 20183:45 pmRNSAdditional Listing
1st Nov 20183:08 pmRNSForm 8.3 - Sinclair Pharma plc
1st Nov 201812:43 pmRNSCourt sanction of the scheme of arrangement
31st Oct 20182:25 pmRNSForm 8.3 - Sinclair Pharma plc
30th Oct 20182:29 pmRNSForm 8.3 - Sinclair Pharma plc
29th Oct 20185:30 pmRNSSinclair Pharma
29th Oct 20182:44 pmRNSForm 8.3 - Sinclair Pharma plc
29th Oct 20189:23 amRNSForm 8.3 - Sinclair Pharma Plc
29th Oct 20188:24 amRNSForm 8.3 - Sinclair Pharma PLC
26th Oct 20188:33 amRNSForm 8.3 - Sinclair Pharma PLC
25th Oct 20189:41 amRNSForm 8.3 - Sinclair Pharma PLC
24th Oct 20183:08 pmRNSForm 8.3 - SINCLAIR Pharma PLC
24th Oct 20182:39 pmRNSResults of Court Meeting and General Meeting
23rd Oct 20183:35 pmRNSForm 8.3 - Sinclair Pharma plc
23rd Oct 20182:23 pmRNSHolding(s) in Company
23rd Oct 201812:37 pmGNWMan Group PLC : Form 8.3 - Sinclair Pharma plc
22nd Oct 201812:00 pmRNSForm 8.5 (EPT/RI) - Sinclair Pharma Plc
19th Oct 20183:01 pmRNSForm 8.3 - SINCLAIR PHARMA PLC
19th Oct 201812:00 pmRNSForm 8.5 (EPT/RI) - Sinclair Pharma Plc
19th Oct 201810:37 amRNSHolding(s) in Company
19th Oct 201810:35 amRNSHolding(s) in Company
18th Oct 20183:20 pmBUSForm 8.3 - Sinclair Pharma PLC
18th Oct 20183:15 pmRNSForm 8.3 - Sinclair Pharma plc
18th Oct 20182:59 pmBUSForm 8.3 - Sinclair Pharma plc
18th Oct 201812:00 pmRNSForm 8.5 (EPT/RI) - Sinclair Pharma Plc
18th Oct 201811:58 amRNSForm 8.3 - Sinclair Pharma Plc
18th Oct 201811:42 amGNWMan Group PLC : Form 8.3 - Sinclair Pharma plc
18th Oct 201810:44 amRNSForm 8.3 - Sinclair Pharma Plc
18th Oct 20189:40 amRNSForm 8.3 - [LMR Partners/Sinclair Pharma]
18th Oct 20187:00 amRNSDisclosure under Rule 2.10(c)
17th Oct 20184:49 pmRNSHolding(s) in Company
17th Oct 20184:46 pmRNSHolding(s) in Company
17th Oct 20183:30 pmRNSForm 8.3 - SPH LN
17th Oct 20183:19 pmRNSForm 8.3 - Sinclair Pharma plc
17th Oct 20183:15 pmRNSForm 8.3 - Sinclair Pharma plc
17th Oct 20183:11 pmRNSForm 8.3 - Sinclair Pharma PLC
17th Oct 20183:11 pmBUSForm 8.3 - Sinclair Pharma plc
17th Oct 20182:38 pmRNSForm 8.3 - Sinclair Pharma Plc
17th Oct 201812:30 pmRNSForm 8.3 - Sinclair Pharma plc
17th Oct 201812:29 pmGNWMan Group PLC : Form 8.3 - Sinclair Pharma plc
17th Oct 201812:20 pmRNSForm 8.3 - Sinclair Pharma Plc
17th Oct 20188:06 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.